期刊
TRENDS IN IMMUNOLOGY
卷 39, 期 11, 页码 900-920出版社
CELL PRESS
DOI: 10.1016/j.it.2018.09.007
关键词
-
类别
资金
- NIH [1 R01 CA219896-01A1]
- US-Israel Binational Science Foundation [201332]
- Kennedy Memorial Foundation [0727030]
- Melanoma Research Alliance [4022024]
- American Association for Cancer Research Stand Up To Cancer [SU2C-AACR-IRG-19-17]
- Department of Defense [W81XWH-16-1-0121]
- MD Anderson Cancer Center Multidisciplinary Research Program Grant
- Andrew Sabin Family Fellows Program
- MD Anderson Cancer Center's Melanoma Moon Shots Program
- Fonds de Recherche Quebec-Sante's (FRQS) Resident Physician Health Research Career Training Program [32667]
- Schissler Foundation
- American Legion Auxiliary Department of Texas
The human microbiome is a complex aggregate of microorganisms, and their genomes exert a number of influences crucial to the metabolic, immunologic, hormonal, and homeostatic function of the host. Recent work, both in preclinical mouse models and human studies, has shed light on the impact of gut and tumor microbiota on responses to systemic anticancer therapeutics. In light of this, strategies to target the microbiome to improve therapeutic responses are underway, including efforts to target gut and intratumoral microbes. Here, we discuss mechanisms by which microbiota may impact systemic and antitumor immunity, in addition to outstanding questions in the field. A deeper understanding of these is critical as we devise putative strategies to target the microbiome.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据